In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Apellis Pharmaceuticals (NASDAQ:APLS) and its primary competitors in the Biotechnology industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.

Apellis Pharmaceuticals Background

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

Company P/E P/B P/S ROE EBITDA (in billions) Gross Profit (in billions) Revenue Growth
Apellis Pharmaceuticals Inc 224.42 13.95 5.23 -15.29% $-0.05 $0.17 -5.94%
Alkermes PLC 24.51 3.21 4.01 2.78% $0.08 $0.34 -10.57%
TG Therapeutics Inc 12.12 8.27 8.79 3.67% $0.05 $0.15 78.0%
ACADIA Pharmaceuticals Inc 9.71 3.10 3.54 25.51% $0.02 $0.26 9.39%
Kiniksa Pharmaceuticals International PLC 64.17 6.49 5.61 2.57% $0.02 $0.11 64.95%
Average 27.63 5.27 5.49 8.63% $0.04 $0.21 35.44%

Through a detailed examination of Apellis Pharmaceuticals, we can deduce the following trends:

  • The current Price to Earnings ratio of 224.42 is 8.12x higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.

  • It could be trading at a premium in relation to its book value, as indicated by its Price to Book ratio of 13.95 which exceeds the industry average by 2.65x.

  • The Price to Sales ratio is 5.23, which is 0.95x the industry average. This suggests a possible undervaluation based on sales performance.

  • The Return on Equity (ROE) of -15.29% is 23.92% below the industry average, suggesting potential inefficiency in utilizing equity to generate profits.

  • The company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $-50 Million, which is -1.25x below the industry average. This potentially indicates lower profitability or financial challenges.

  • The gross profit of $170 Million is 0.81x below that of its industry, suggesting potential lower revenue after accounting for production costs.

  • The company's revenue growth of -5.94% is significantly lower compared to the industry average of 35.44%. This indicates a potential fall in the company's sales performance.

Debt To Equity Ratio

debt to equity

The debt-to-equity (D/E) ratio helps evaluate the capital structure and financial leverage of a company.

Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.

When examining Apellis Pharmaceuticals in comparison to its top 4 peers with respect to the Debt-to-Equity ratio, the following information becomes apparent:

  • Among its top 4 peers, Apellis Pharmaceuticals has a higher debt-to-equity ratio of 1.28.

  • This implies a greater reliance on debt financing, which can expose the company to higher financial risk and potential challenges.

Key Takeaways

For Apellis Pharmaceuticals, the PE and PB ratios are high compared to peers, indicating overvaluation. The PS ratio is low, suggesting potential undervaluation based on revenue. In terms of ROE, EBITDA, gross profit, and revenue growth, Apellis Pharmaceuticals lags behind industry peers, reflecting weaker financial performance and growth prospects.

This article was generated by Benzinga's automated content engine and reviewed by an editor.